Dysbiosis in early sepsis can be modulated by a multispecies probiotic: a randomised controlled pilot trial

Benef Microbes. 2019 Apr 19;10(3):265-278. doi: 10.3920/BM2018.0067. Epub 2019 Jan 29.

Abstract

The gut is hypothesised to play an important role in the development and progression of sepsis. It is however unknown whether the gut microbiome and the gut barrier function is already altered early in sepsis development and whether it is possible to modulate the microbiome in early sepsis. Therefore, a randomised, double blind, placebo-controlled pilot study to examine the alterations of the microbiome and the gut barrier in early sepsis and the influence of a concomitant probiotic intervention on dysbiosis at this early stage of the disease was conducted. Patients with early sepsis, defined as fulfilling the sepsis definition from the 2012 Surviving Sepsis Campaign guidelines but without signs of organ failure, received multispecies probiotic (Winclove 607 based on Omnibiotic® 10 AAD) for 28 days. Gut microbiome composition, function, gut barrier and bacterial translocation were studied. Patients with early sepsis had a significantly lower structural and functional alpha diversity, clustered differently and showed structural alterations on all taxonomic levels. Gut permeability was unaltered but endotoxin, endotoxin binding proteins and peptidoglycans were elevated in early sepsis patients compared to controls. Probiotic intervention successfully increased probiotic strains in stool and led to an improvement of functional diversity. Microbiome composition and function are altered in early sepsis. Probiotic intervention successfully modulates the microbiome and is therefore a promising tool for early intervention in sepsis.

Keywords: diversity; gut barrier; inflammation; microbiome.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Bacteria / classification
  • Bacteria / genetics
  • Bacterial Translocation / drug effects
  • Biodiversity
  • Double-Blind Method
  • Dysbiosis / drug therapy*
  • Feces / microbiology
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • Humans
  • Intestinal Mucosa / drug effects
  • Male
  • Middle Aged
  • Pilot Projects
  • Probiotics / administration & dosage*
  • Probiotics / pharmacology*
  • Sepsis / drug therapy*
  • Treatment Outcome